Related Experiment Video
Updated: Jun 25, 2025

10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
13.7K
B-cell prolymphocytic leukemia: an enduring bona fide entity.
Miguel S Gonzalez-Mancera1, Jean Lopategui1, David Hoffman2
1Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, South Tower, Room 4707, Los Angeles, USA.
International Journal of Hematology
|May 26, 2024
Summary
This case study highlights a de novo presentation of B-cell prolymphocytic leukemia (B-PLL), a condition recently removed from the WHO-HAEM5 classification. Despite its exclusion, this diagnosis was confirmed through comprehensive clinical and laboratory analysis.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- B-cell prolymphocytic leukemia (B-PLL) was recognized in the WHO-HAEM4 classification.
- The de novo presentation of B-PLL has been removed from the upcoming WHO-HAEM5 classification.
- This change necessitates careful evaluation of B-PLL cases.
Observation:
- A 65-year-old male presented with leukocytosis and fatigue.
- Imaging revealed no organomegaly.
- Bone marrow examination identified a prolymphocytoid population constituting 78% of marrow elements.
Findings:
- After excluding other hematolymphoid neoplasms, the case was diagnosed as de novo B-cell prolymphocytic leukemia.
- The diagnosis was supported by clinical parameters and ancillary methods.
- This case underscores the importance of recognizing B-PLL despite classification changes.
Implications:
- This case emphasizes the continued clinical relevance of B-cell prolymphocytic leukemia.
- It highlights the need for accurate diagnosis and classification of hematolymphoid neoplasms.
- Further research may be warranted to clarify the status of de novo B-PLL in future classifications.
Related Concept Videos
Disorders of Leukocytes
938
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
938
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K

